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http://dx.doi.org/10.1016/j.ijrobp.2014.04.029Purpose: This study describes the early clinical outcomes of a prospective phase 2
study of consolidative involved-node proton therapy (INPT) as a component of
combined-mode therapy in patients with stages I to III Hodgkin lymphoma (HL) with
mediastinal involvement.
Methods and Materials: Between September 2009 and June 2013, 15 patients with
newly diagnosed HL received INPT after completing chemotherapy in an institutional
review board-approved protocol comparing the dosimetric impact of PT with those of
three-dimensional conformal radiation therapy (3DCRT) and intensity modulated RT.
Based on 18F-Fluorodeoxyglucose positron emission tomography/computed tomogra-
phy (18F-FDG PET/CT) response, 5 children received 15 to 25.5 cobalt Gy equivalent
(CGE) of INPT after receiving 4 cycles of Adriamycin, Bleomycin, Vincristine, Etopo-
side, Prednisone, Cyclophosphamide or Vincristine, adriamycin, methotrexate, Predni-
sone chemotherapy, and 10 adults received 30.6 to 39.6 CGE of INPT after 3 to 6
cycles of Adriamycin, Bleomycine, Vinblastine, Dacarbazine. Patients were routinelyMD, MPH, University of
rson St. Jacksonville, FL
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.0/).
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radiation-induced late ef-
fects, proton therapy
following chemotherapy in
Hodgkin lymphoma patients
is well tolerated, and disease
outcomes are similar to those
in conventional photon
therapy.evaluated for toxicity during and after treatment, using Common Terminology Criteria
for Adverse Events, version 3.0, and for relapse by physical examination and routine
imaging. Relapse-free survival (RFS) and event-free survival (EFS) rates were calcu-
lated using the Kaplan-Meier method from the time of diagnosis.
Results: The median follow-up was 37 months (range, 26-55). Two events occurred
during follow-up: 1 relapse (inside and outside the targeted field) and 1 transformation
into a primary mediastinal large B cell lymphoma. The 3-year RFS rate was 93%, and
the 3-year EFS rate was 87%. No acute or late grade 3 nonhematologic toxicities were
observed.
Conclusions: Although decades of follow-up will be needed to realize the likely
benefit of PT in reducing the risk of radiation-induced late effects, PT following
chemotherapy in patients with HL is well-tolerated, and disease outcomes were similar
to those of conventional photon therapy.  2014 Authors. Published by Elsevier Inc.Introduction
Despite remarkable success in treating patients with
Hodgkin lymphoma (HL), each year a large proportion of
patients die from treatment-related effects of radiation
therapy (RT) and chemotherapy. As the late effects of HL
therapies continue to emerge with increased survivorship, a
primary goal of current international clinical trials in early-
stage and intermediate risk HL is the development of less
toxic interventions. Strategies in RT include reducing doses
and treatment volumes. Omitting radiation altogether in
patients who can be cured with minimally toxic chemo-
therapy has also been considered, despite the substantial
number of HL patients who continue to benefit from RT (1,
2). The 2 most recent thrusts within the RT community
have been to treat a minimal target volume, the “involved
node” or “involved site” as defined by volumetric and
positron emission tomography (PET) imaging, and to
modify radiation doses based on chemotherapy response.
The availability of protons as a source of radiation in
lieu of photons allows for yet another strategy: the reduc-
tion of “integral dose,” or dose inadvertently deposited
outside the targeted area along the entrance and exit of the
beam path. With photon-based radiation, the dose along the
beam’s entrance path exceeds the target dose, and sub-
stantial dose is deposited along the exit portion of the beam,
usually resulting in deposition of more radiation dose
outside rather than inside the target. Newer RT strategies,
such as intensity modulated RT (IMRT), can redistribute
this integral dose to produce a more favorable distribution
of integral dose than conventional 3-dimensional conformal
RT (3DCRT), but these strategies do not usually substan-
tially reduce the dose. With protons, there is no exit dose,
and the entrance dose is much lower than the target dose,
resulting in most of the radiation dose being deposited in-
side the target (rather than outside of it). This marked
reduction in integral dose with protons is predicted to result
in a significant reduction in late effects from RT.
Investigators at the University of Florida conducted a
prospective study comparing dosimetric parameters ofproton therapy with those of 3DCRT and IMRT in patients
with stages I to IIIB HL involving the mediastinum. Pa-
tients were offered treatment with the modality that best
spared the organs at risk (OARs). The dosimetric outcomes
of the study were reported previously (3), but the early
clinical outcome with involved-node proton therapy (INPT)
is the subject of this report and the first report in the
literature using this strategy.
Methods and Materials
Institution review board UFJ-2008-161 (HL01) was a pro-
spective institutional review board-approved comparative
dosimetry trial of PT, IMRT, and 3DCRT for patients with
newly diagnosed HL. After patient simulation and target
delineation, all enrolled patients had 3 treatment plans
created. Once the requisite target coverage goals were met,
the secondary treatment plan goal was the maximum
reduction of dose to OARs, including the heart and lungs.
The plan that delivered 4 Gy or higher to the lowest volume
of body (lowest body V4) was deemed the best plan and
offered to the patient.
From June 2009 through June 2013, 22 patients were
seen at University of Florida Proton Therapy Institute
(UFPTI) and met the following eligibility criteria: stages I
to IIIB classical HL with mediastinal involvement, pre
chemotherapy 18F-Fluorodeoxyglucose Positron Emission
Tomography/Computed Tomography (18F-FDG PET/CT)
scan, and either a complete response or partial response
(PR) by 18F-FDG PET/CT scan after standard chemo-
therapy. Of all eligible patients we saw in our clinic, 1
patient refused enrollment in favor of standard photon-
based involved-field RT, and 1 patient was missed at
screening and not offered the protocol, resulting in 20 pa-
tients enrolled in HL01. Two of these patients were later
withdrawn due to either progression of disease prior to
starting RT or misclassification as stage IIIBE with exten-
sive bilateral FDG-avid pleural involvement and malignant
pleural effusion rather than the correct classification of
stage IVB HL (4). The median patient age was 23 years
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133 miles (range, 5-1470 miles) for consultation.
At simulation, an attempt was made to reproduce the
initial 18F-FDG PET/CT scan position. Patients with arms
positioned above the head in the pre chemotherapy
18F-FDG PET/CT scan underwent simulation with a wing
board, whereas those with arms down had a pull rope to
reproduce clavicle positioning on a daily basis. Positioning
was secured and reproduced each day by using a posi-
tioning cushion (Vac-Lok bag; Civco Medical Solutions,
Kalona, IA), and face mask (Aquaplast; Qfix, Avondale,
PA) for patients with neck disease (3). Both a 4D CT scan
and a 3D CT scan with contrast (Philips Brilliance; Philips
Medical Systems, Madison, WI) were performed in each
patient. Although the deep inspiration breath-hold tech-
nique was allowed, only 1 patient was treated in this
manner because the pre chemotherapy scans for most pa-
tients were carried out as they breathed freely. In-
consistencies between the 2 image sets would have
precluded the ability to accurately perform INRT target
delineation, otherwise. The images were uploaded to a
MIMvista workstation (MIMvista Corp, Cleveland, OH)
and fused with the patient’s pre chemotherapy 18F-FDG
PET/CT scan and diagnostic CT scans of the neck, chest,
abdomen, and pelvis. Target delineation included gross
residual tumor volume (GTV), clinical target volume
(CTV), and planning target volume (PTV) of the involved
nodes according to European Organization for Research
and Treatment of Cancer (EORTC) guidelines (5). A
modification to the EORTC guidelines was required
because most patients were referred from outside in-
stitutions after completing chemotherapy, thereby prevent-
ing us from performing the pre chemotherapy 18F-FDG
PET/CT scan in the exact treatment planning position with
all of the correct immobilization devices. Although
extremely time consuming for the patient and radiation
therapists, our solution was to match the initial pre
chemotherapy imaging positioning at the time of simula-
tion to the best of our ability. All OARs within the target
region were contoured, including the heart, lungs, esoph-
agus, thyroid, and breasts (in women only). Photon-based
treatment was planned using a Pinnacle workstation (Phi-
lips Healthcare, Andover, MA) and included a 3DCRT
treatment plan with traditional anterior-posterior (AP)/
posterior-anterior (PA) treatment fields and an IMRT
treatment plan using 5 to 7 fields. Proton therapy was
planned using an Eclipse workstation (Varian Medical
Systems, Palo Alto, CA) with 1 to 7 treatment fields using
the average scan developed from the 4D CT scan. Per
protocol, treatment planning for each of the 3 techniques
prioritized PTV coverage whereby, 95% of the PTV was to
receive at least 95% of the prescription dose (PTV
D95%>95%). Once target coverage was optimized, mini-
mization of dose to the OARs was prioritized as follows:
heart > lung > breast (women only) > esophagus. Radi-
ation prescription dose was 15 to 21 Gy at 1.5 Gy per
fraction for pediatric patients and 30.6 Gy at 1.8 Gy perfraction for adult patients. An additional 4.5 to 9 Gy was
given to sites with incomplete CT and/or PET response
following chemotherapy.
In all cases, INPT delivered both a lower body V4 Gy
and lower OAR doses than either 3DCRT or IMRT, so all
20 patients were offered treatment with INPT. Colorwash
dose distribution for one of the patients across all 3 treat-
ment plans is presented in Figure 1. Fourteen patients were
treated with INPT; 1 patient received INRT by combined
IMRT and proton therapy plan because of temporary field-
size limitations with proton therapy; 1 patient who was
errantly enrolled with stage IVB HL was treated with a
modified INPT plan as there are no guidelines for target
delineation for extensive pleural disease and malignant
effusions; and 1 patient received standard involved-field
proton therapy to 45 Gy because of disease progression
after simulation. The remaining 3 patients elected to
receive photon-based RT at local facilities for convenience,
including a 55-year-old man who lived 92 miles from
UFPTI, a 36-year-old woman who lived 166 miles away,
and a 23-year-old woman who lived 355 miles away. A
description of patient baseline characteristics is reported in
Table 1. The median transverse dimension of greatest dis-
ease bulk was 9.25 cm, and median cranial-caudal dimen-
sion was 12 cm.
Toxicities were assessed using the Common Terminol-
ogy Criteria for Adverse Events, version 3.0 (6). Patients
underwent toxicity evaluation weekly during treatment,
1 month after treatment, then every 3 months for 2 years,
and every 6 months thereafter. Imaging was performed at
least annually with an 18F-FDG PET/CT or CT scan, along
with basic blood tests, including erythrocyte sedimentation
rate every 3 months.
This study was designed to have at least 90% power and
95% confidence to detect a 50% reduction in total body
volume V4 relative to either IMRT or conventional therapy;
the standard deviation in all arms was assumed to be 15%. At
least 5 patients were required for the analysis, but because the
proton plans were compared to 2 different modalities, the
required minimum sample size was doubled to 10 patients to
control the experiment-wise error rate at 5%. This minimum
sample was doubled again to 20 patients to account for the
chance of ineligibility, the patient choosing to be treated
elsewhere, or the patient not returning for treatment or
follow-up after dose-volume histogram data were acquired.
Patient follow-up time was calculated from day 1 of proton
therapy. Relapse-free and event-free survival rates were
calculated using the Kaplan-Meier product limit method
starting from day 1 of proton therapy.Results
Dosimetric analysis
Table 2 lists the average dose to the OARs and the integral
body dose, along with the dose differences between 3DCRT
Fig. 1. (A) Radiation treatment plans using 3DCRT (left), protons (middle), and IMRT (right). The CTV is contoured in red
and the PTV in blue with a color-wash dose distribution. (B) Pre chemotherapy positron emission tomography maximum
intensity projection image for the same patient in A (left) and the single anterior field proton arrangement for the same patient
(right). The PTV is shown in blue and the CTV in violet. The heart is shown in red and the lungs in yellow. 3DCRT Z 3-
dimensional conformal RT; CTV Z clinical tumor volume; IMRT Z intensity modulated RT; PTV Z planning target
volume. A color version of this Figure is available at www.redjournal.org.
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and IMRT for all patients enrolled in the study. The integral
dose was reduced with proton therapy by an average of 69
joules (J) (relative reduction [RR] Z 57%) with 3DCRT
and an average of 50 J (RR Z 49%) with IMRT. On the
other hand, the integral dose was reduced only by 19 J (RR
Z 14%) with IMRT compared to that with 3DCRT. The
mean heart dose was reduced with proton therapy by 7.6 Gy
(RR Z 46%) compared with 3DCRT and 3.3 Gy (RR Z
27%) compared with IMRT. IMRT reduced the mean heart
dose by 4.3 Gy (RR Z 25%) compared to that with
3DCRT. Proton therapy also reduced the mean lung dose by
4.5 Gy and 2.7 Gy compared to those with 3DCRT and
IMRT, respectively, whereas the mean lung dose was
reduced only by 1.8 Gy with IMRT compared to that with
3DCRT. Among women, proton therapy reduced the mean
breast dose by an average of 2.1 Gy and 1.7 Gy compared
to those with 3DCRT and IMRT, respectively; the meanbreast dose was reduced only by 0.3 Gy with IMRT
compared to that with 3DCRT.
Clinical outcomes
The median duration of follow-up for the patients treated in
the protocol was 37 months (range, 26-55 months). Among
the 15 patients treated with INPT (excluding the patient
who had progression prior to radiation and the patient with
stage IV B), the chemotherapy regimens consisted of
ABVE-PC for 4 cycles (nZ4), VAMP for 4 cycles (nZ1),
ABVD for 3 cycles (nZ1), ABVD for 4 cycles (nZ2),
ABVD for 5 cycles (nZ1), and ABVD for 6 cycles (nZ6).
The 3-year relapse-free survival and event-free survival
rates were 93% (95% confidence interval [CI], 65%-99%)
and 87% (95% CI, 59%-97%). Two events have since
occurred among these patients, including 1 relapse of HL
and 1 diagnosis of primary mediastinal B cell lymphoma
Table 1 Patient and disease characteristics
Characteristic All INPT Other TX
Sex
Male 5 4 1
Female 15 11 4
Age group
Adult 14 10 4
Pediatric 6 5 1
Mediastinal bulk
MMR>0.33 15 12 3
MMR<0.33 5 3 2
Stage
IAX 1 1 0
IBX 1 1 0
IIA 4 2 2
IIAX 4 3 1
IIAEX 1 1 0
IIBX 7 6 1
IIIAX 1 1 0
IVBX 1 0 1
ESR (mm/h)
NA 2 1 1
<20 1 0 1
20-50 7 6 1
>50 10 8 2
18F-FDG PET/CT response following chemotherapy
PR 3 2 1
CR 17 13 4
Abbreviations: CR Z complete response; ESR Z erythrocyte
sedimentation rate; INPT Z involved-node proton therapy; MMR Z
mediastinal mass ratio; NA Z not available; 18F-FDG PET/CT Z
18F-Fluorodeoxyglucose Positron Emission Tomography/Computed
Tomography; PR Z partial response; TX Z treatment.
Table 2 Average dose to the organs at risk among the
different radiation therapy techniques for all patients enrolled
in the study
Structure
3DCRT IMRT PT
Mean SD Mean SD Mean SD
Integral dose
(joules)
122.9 62.3 103.8 48.6 53.6 32.0
Heart (Gy) 16.5 7.6 12.3 6.2 8.9 5.1
Lung (Gy) 11.6 3.7 9.8 2.8 7.1 2.5
Breast (Gy) 6.3 3.5 6.0 3.4 4.3 3.0
Thyroid (Gy) 19.3 10.1 17.7 9.3 15.8 9.7
Esophagus (Gy) 20.3 4.8 16.4 3.9 13.4 5.6
Abbreviations: 3DCRT Z 3-dimensional conformal radiation ther-
apy; IMRT Z intensity modulated radiation therapy; PT Z proton
therapy.
Table 3 Acute* and late
y
grade 1 and 2 toxicities
Toxicity
No. of acute
occurrences
No. of late
occurrences
Grade 1 Grade 2 Grade 1 Grade 2
Anxiety/depression NA NA 5 0
Performance status 2 0 2 0
Fatigue 4 0 8 0
Pulmonary toxicity 8 0 13 0
Esophagitis 10 3 4 0
Chest pain 3 0 5 0
Xerostomia 5 0 3 0
Skin toxicity 14 1 11 0
Abbreviation: NA Z not available.
* Acute is defined as <90 days from the start of treatment.
y Late is defined as >90 days from the start of treatment.
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HL treated with 4 cycles of ABVE-PC chemotherapy and
characterized as a slow responder by interim 18F-FDG PET/
CT scan followed by 25.5 Gy had a relapse within 6 months
of completing proton therapy. The relapse occurred both in
the field and out of field. A 20-year-old female with bulky
stage IIB mediastinal HL with a PR by 18F-FDG PET/CT
following ABVD for 6 cycles received consolidative INPT
to 30.6 Gy with a boost to the residual FDG-avid disease of
9.6 Gy (for a total dose of 39.6 Gy). Although her 18F-FDG
PET/CT scan 3 months after INPT showed a continuing
PR, a repeat scan 3 months later showed progression within
the previously FDG-avid mediastinal region, which was
found to be positive for PMBCL by biopsy. Between the 2
patients found to be ineligible for the protocol following
enrollment, 1 had no evidence of disease by 18F-FDG PET/
CT scan at more than 6 months following proton therapy,
whereas the other had rapid progression within 6 months.
Toxicity
No patient developed grade 3 or higher toxicity during follow-
up. Acute (<90 days from the start of treatment) and late (>90
days) grade 1 and 2 toxicities are reported in Table 3. Thepatient who received combined IMRT and proton therapy
developed hypothyroidism temporarily requiring levothyrox-
ine sodium tablets following treatment. One patient, who
developed bleomycin-induced lung toxicity during chemo-
therapy, developed radiographic pneumonitis, seenonCTscan
3 months following treatment, and was treated with cortico-
steroids despite being asymptomatic.Discussion
This study represents the first prospective clinical trial to
evaluate the use of proton therapy in the management of
HL with involved-node therapy. The study demonstrates
statistically significant and clinically relevant reductions in
the radiation dose to OARs and normal tissue and in inte-
gral dose with proton therapy compared with photon-based
RT treatment. Furthermore, this study demonstrated control
rates that were similar to those expected with conventional
radiation treatment (7, 8).
International efforts in radiation-related toxicity reduc-
tion in the treatment of HL have led to the definition of a
new minimal radiation target, for example, the involved
node; and in cases of ambiguous imaging, a slightly larger,
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be used (9). This study focused on an additional new
strategy for reduction of radiation-related toxicity in HL
patients: use of protons as a radiation source in lieu of
traditional photons to reduce overall integral dose, or
inadvertent radiation dose to nontargeted normal tissues,
and inadvertent doses to specific OARs such as heart and
lung, sites typically at risk for late radiation effects. Thus,
INPT represents the greatest minimization of inadvertent
radiation exposure to nontargeted tissues possible thus far
in the longstanding continuing international effort to
decrease radiation toxicity while maintaining radiation ef-
ficacy in HL.
Proton therapy in the management of lymphoma is not a
novel concept, but it has not yet been widely used (10).
Several dosimetry studies have been reported that describe
the advantages of proton therapy in HL as a way of reducing
radiation dose to the heart, breast, and lungs (11-14), but all of
these studies were retrospective, and none of them actually
treated the patients with proton therapy. The present study is
the first prospective dosimetry study that consequently
offered patients’ treatment with whichever treatment plan
accomplished target coverage and best spared the OARs.
Importantly, in all 20 patients, the proton therapy plan offered
dose reductions compared to either the 3DCRT or IMRT
plans that were expected to reduce the risk of radiation-
induced cardiac events and/or radiation-induced cancers
among survivors.
Although the dose reductions to the specific OARs
varied, with some patients enjoying considerably more
benefits from proton therapy than others, the average inte-
gral dose to the body was reduced using proton therapy for
all patients by 50% to 60%. The integral dose reflects total-
body radiation exposure and has been associated with a
higher risk of death from radiation-induced cancers. In a
study of survivors of childhood cancer by Tukenova et al
(15), integral radiation doses >150 J were associated with a
2-fold higher risk of death due to radiation-induced carci-
noma and a 12.5-fold higher risk of death from a radiation-
induced sarcoma compared with patients who received less
than 150 J. Thus, we expect the integral dose reduction seen
with the use of proton therapy would be associated with a
reduced risk of secondary cancers.
In this study, for all patients, the mean reduction in heart
dose with proton therapy compared with 3DCRT was 7.6
Gy. A recent report by Darby et al (16) demonstrated an
increased relative risk of major coronary events with mean
doses to the heart by 7.4% per Gy and no threshold among
breast cancer survivors (average age >60 years at the time
of irradiation). Thus, based on results from the present
study, we would expect a 56% increased RR of a major
coronary event with 3DCRT compared with proton therapy.
These results, however, are based on cardiac irradiation in
breast cancer survivors and do not factor in the early age of
cardiac irradiation typically seen in patients with HL (the
mean age in our study population was 23 years old); thus,
the RR is likely even higher. Taken together with the >50%reduction in integral dose and the expected reduction in
secondary neoplasms, the overall benefits of using proton
therapy are considerable.
Although this series is small and patients’ disease stages
varied, the early outcomes from patients treated in this trial
are similar to those reported recently by others (7, 8).
Importantly we included both pediatric and adult patients
and the majority of the patients treated in the present study
had aggressive disease, including 75% with bulky medi-
astinal involvement and patients with stage III disease.
Consequently, most patients were referred by outside ra-
diation oncologists (only 5 lived within 50 miles of UFPTI)
because of the challenges of having to deliver photon-based
radiation to patients with bulky mediastinal disease and
multiple nodal stations. Because we expected most of the
patients would come from outside referrals by radiation
oncologists after the patients completed chemotherapy, the
protocol did not require a specific chemotherapy regimen.
This is a limitation to the study because several chemo-
therapy regimens were used.
Although the toxicity of INPTwas limited, the important
benefits of reduced cardiac disease, secondary cancers, and
other chronic problems will not be evident for decades.
Nevertheless, considering the abundant data for the negative
impact of radiation to normal tissue among survivors of HL,
the National Comprehensive Cancer Network Hodgkin
guidelines committee endorses the use of proton therapy in
the management of HL along with IMRT and the new radi-
ation field design, involved-site RT (17).
The potential benefits of proton therapy are not limited
to the primary management of HL but can be extrapolated
to its use in radiation-naı¨ve patients for whom single-mode
therapy (chemotherapy alone) failed and who are receiving
second-line therapy in combination with high-dose
chemotherapy and autologous stem cell rescue for re-
fractory or relapsed HL (18). These patients are at even
higher risk of late effects from their overall treatment
course and may, in fact, benefit even more than those in the
first-line setting (18-20).
Conclusions
INPT reduced the dose to the OARs and total-body dose
compared with 3DCRT or IMRT. Clinical disease control
outcomes 3 years after completing treatment are similar to
those of 3DCRT to an involved field RT field. Proton
therapy is an important new strategy for RT, offering pa-
tients seeking the most effective and safe treatment avail-
able for HL.References
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